Cell therapy for relapsed or refractory AML with NPM1 mutation
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new type of cell therapy, called MB-dNPM1-TCR.1, for people with acute myeloid leukemia (AML) that has returned or not responded to standard treatments. The therapy uses your own immune cells, which are specially trained to find and attack leukemia cells that have a specific mutation in the NPM1 gene.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your leukemia (AML) has come back or hasn't gotten better after at least two rounds of standard treatment.
- You must have a specific blood marker called HLA-A*02:01.
- Your leukemia cells must have a mutation in the NPM1 gene.
- You need to have a white blood cell count of at least 1000, with less than half of those cells being leukemia cells.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new kind of immune cell therapy (called BSB-2002) for people with a specific type of AML that has returned or not responded to standard treatment. The therapy is made from your own white blood cells, given after a short course of chemotherapy to prepare your body.
This trial studies whether a combination medicine (ATO plus ATRA) is safe and works better in people with a specific type of AML (acute myeloid leukemia) caused by an NPM1 mutation. You would join only after your leukemia has reached remission, meaning the active leukemia has cleared after initial treatment.
This trial tests a new drug for people with acute myeloid leukemia (AML) that has come back or hasn't responded to standard therapies, and whose leukemia has certain genetic markers. The drug may target these specific changes to help stop the cancer.
This trial tests a personalized cell therapy that uses your own immune cells (T cells) to target a specific protein (AML1-ETO) found in certain AML cells. It is for patients whose leukemia has come back or not gone away after standard treatment.
This study tests a new experimental drug (NMS-03597812) for adults with AML that has not responded to or has returned after other treatments. The goal is to see if it is safe and if it can help control the leukemia.
This trial tests a new type of cell therapy called NKG2D CAR-T for people with AML that has not responded to standard treatment or has come back. It aims to use your own immune cells, modified to attack the leukemia, to help you achieve remission.
Hear when a new Leukemia, Myeloid, Acute trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.